PIQ should soon be able to add cardiovascular disease to that list in the pipeline, iMO. Endometriosis, Gastro, Asthma & Lung disease are still at the pre-clinical stage. These are all globally significant opportunities.
Meanwhile, promarkerD for diabetic kidney disease is being rolled out around the world. It has passed all of the clinical studies
https://promarkerd.com/science/clinical-studies/
Sales revenue expected Q1 2019. Potentially, millions then hundreds of millions and yet, the market hasn't woken up. Market cap should be at least over $100m by now.
PIQ should soon be able to add cardiovascular disease to that...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $60.56M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $51.50K | 144.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18336 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9405 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |